



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of PRECAUTIONS

**Alacepril, Imidapril hydrochloride, Enalapril maleate, Captopril, Quinapril hydrochloride, Cilazapril hydrate, Temocapril hydrochloride, Delapril hydrochloride, Trandolapril, Benazepril hydrochloride, Perindopril erbumine, and Lisinopril hydrate**

June 3, 2014

### Non-proprietary Name

- Alacepril
- Imidapril hydrochloride
- Enalapril maleate
- Captopril
- Quinapril hydrochloride
- Cilazapril hydrate
- Temocapril hydrochloride
- Delapril hydrochloride
- Trandolapril
- Benazepril hydrochloride
- Perindopril erbumine
- Lisinopril hydrate

### Safety measure

Precautions section should be revised in the package inserts.

In Precautions for concomitant use subsection of Interactions section, the following texts should be added (underlined parts are revised):

#### Angiotensin II receptor blockers (ARBs)

##### Clinical symptoms and measures:

Renal impairment, hyperkalaemia, and/or hypotension may occur. Patients should be carefully monitored for renal function, serum potassium level, and blood pressure.

##### Mechanism and risk factors:

Concomitant use with ARBs may increase an effect of renin-angiotensin system blockade.